A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity Reaction
Stacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.
Recent Advancements and Future Directions in Frontline Treatment of Multiple Myeloma
Kimberley R. Doucette, MD, MSC; and David H. Vesole, MD, PhD, discuss updates to frontline treatment in multiple myeloma.
Current Frontline Treatment of Multiple Myeloma
Sarah A. Holstein, MD, PhD, reviews updated treatment options for patients with newly diagnosed multiple myeloma.
Bridging the Gaps: Taking Care of the Whole Person
Sheila Lahijani, MD, FACLP, gives her perspective on the need for psycho-oncologists to help patients during their cancer journeys.
Caring for Patients With Serious Mental Illness: Guide for the Oncology Clinician
Veronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.
Ajai Chari, MD, Talks Diversity in Multiple Myeloma Research
“What is more gratifying than people who are alive in complete remission for years?...The therapeutics are so effective and the symptoms of myeloma can be so rapidly reversed. It’s really gratifying.”
Platinum Hypersensitivity Reaction (HSR): An Ongoing Problem in Cancer Treatment
In this month's Letter to the Readers, ONCOLOGY co-editor-in-chief Howard S. Hochster, MD, discusses oxaliplatin hypersensitivity reaction in gastrointestinal cancer.
2 Clarke Drive Cranbury, NJ 08512